Poxel
POXEL | PA
Overview
Corporate Details
- ISIN(s):
- FR0012432516
- LEI:
- 9695003OIX0T7NX72N26
- Country:
- France
- Address:
- 259 AVENUE JEAN JAURES, 69007 LYON
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterium-modified thiazolidinedione (dTZD) platforms targeting chronic and rare metabolic diseases. Poxel’s first-in-class lead product, TWYMEEG® (Imeglimin), that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-13 07:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 153.8 KB | |
| 2025-05-13 07:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 130.6 KB | |
| 2025-05-06 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 84.4 KB | |
| 2025-04-16 18:03 |
Earnings Release
Inside Information / Other news releases
|
English | 216.7 KB | |
| 2025-04-16 18:03 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 107.6 KB | |
| 2025-04-08 18:11 |
Regulatory News Service
Inside Information / Other news releases
|
English | 145.4 KB | |
| 2025-04-08 18:11 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 126.2 KB | |
| 2025-04-04 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 76.2 KB | |
| 2025-03-31 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 96.9 KB | |
| 2025-03-31 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 88.4 KB | |
| 2025-03-20 21:45 |
Regulatory News Service
Inside Information / Other news releases
|
English | 114.5 KB | |
| 2025-03-20 21:45 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 94.2 KB | |
| 2025-03-04 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Poxel : nombre d’actions et de droits de vote composant le capital social
|
French | 99.0 KB | |
| 2025-01-23 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 90.3 KB | |
| 2025-01-23 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 81.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-29 | N/A | Other | Buy | 80,000 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
European Institute of Science AB | Sweden | EURI B | |
|
European Medical Solutions | Belgium | ALEMS | |
|
Evogene Ltd. | Israel | EVGN | |
|
Evolva Holding SA | Switzerland | EVE | |
|
EXACT Therapeutics AS | Norway | EXTX | |
|
Exosens | France | EXENS | |
|
ExpreS2ion Biotech Holding AB | Sweden | EXPRS2 | |
|
Fermentalg | France | ALGAE | |
|
Formycon AG | Germany | FYB | |
|
FRONTIER IP GROUP PLC | United Kingdom | FIPP |